Evaluation of vascular risk in patients with migraine with and without aura treated with erenumab: Post hoc analysis of pooled long‐term clinical trial data

To assess cardiovascular (CV) safety of erenumab in clinical trial patients associated with degree of CV risk.

[1]  D. Dodick,et al.  Risk of hypertension in erenumab‐treated patients with migraine: Analyses of clinical trial and postmarketing data , 2021, Headache.

[2]  S. Silberstein,et al.  Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial , 2021, European journal of neurology.

[3]  A. Brinker,et al.  Hypertension: A new safety risk for patients treated with erenumab , 2021, Headache.

[4]  M. Ferrari,et al.  Anti‐migraine Calcitonin Gene–Related Peptide Receptor Antagonists Worsen Cerebral Ischemic Outcome in Mice , 2020, Annals of neurology.

[5]  S. Silberstein,et al.  Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study , 2020, Cephalalgia : an international journal of headache.

[6]  D. Dodick,et al.  Vascular safety of erenumab for migraine prevention , 2019, Neurology.

[7]  L. Edvinsson,et al.  Erenumab (AMG 334), a monoclonal antagonist antibody against the canonical CGRP receptor, does not impair vasodilatory or contractile responses to other vasoactive agents in human isolated cranial arteries , 2019, Cephalalgia : an international journal of headache.

[8]  R. Davies,et al.  Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. , 2019, Regulatory toxicology and pharmacology : RTP.

[9]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.

[10]  A. van Hecken,et al.  Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers , 2018, Cephalalgia : an international journal of headache.

[11]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American College of Cardiology.

[12]  C. Depré,et al.  A Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina , 2018, Headache.

[13]  D. Dodick,et al.  ARISE: A Phase 3 randomized trial of erenumab for episodic migraine , 2018, Cephalalgia : an international journal of headache.

[14]  P. Muntner,et al.  Response to Letter to editor "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults". , 2018, Journal of the American Society of Hypertension : JASH.

[15]  P. Goadsby,et al.  A Controlled Trial of Erenumab for Episodic Migraine , 2017, The New England journal of medicine.

[16]  R. Lipton,et al.  Framingham‐Based Cardiovascular Risk Estimates Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study , 2017, Headache.

[17]  S. Silberstein,et al.  Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial , 2017, The Lancet Neurology.

[18]  T. Kurth,et al.  Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study , 2017, Headache.

[19]  S. Silberstein,et al.  Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial , 2016, The Lancet Neurology.

[20]  S. Brain,et al.  Calcitonin gene-related peptide: physiology and pathophysiology. , 2014, Physiological reviews.

[21]  N. Murinova,et al.  Vascular Risk in Migraineurs: Interaction of Endothelial and Cortical Excitability Factors , 2014, Headache.

[22]  J. Olesen,et al.  Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers , 2010, Neurology.

[23]  S. Brain,et al.  Vascular actions of calcitonin gene-related peptide and adrenomedullin. , 2004, Physiological reviews.

[24]  S. Silberstein,et al.  Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study , 2020 .

[25]  S. Grundy,et al.  National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .